Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Asymmetric DNA-based OrganoCatalysis

Project description

Revolutionising drug synthesis with DNA

Metal-based asymmetric catalysis is a powerful method for the synthesis of complex chiral molecules such as those required in drug development and materials science. However, the use of transition metals is associated with toxicity and high cost. Organocatalysis has emerged as a greener alternative that employs stable, metal-free small molecules for sustainable synthesis. With the support of the Marie Skłodowska-Curie Actions programme, the DNAOrgCat project proposes to create new catalysts that combine DNA oligonucleotides with catalytic molecules. The DNA acts like a flexible scaffold that can hold and position the catalytic part while its unique shape leads to high selectivity. Moreover, the DNA is biodegradable and can be recycled to achieve a greener and more sustainable approach.

Objective

Asymmetric catalysis is arguable the most appealing way to prepare complex chiral scaffolds. In this context, metal-catalyzed transformations have been more widely used in comparison to metal-free strategies. Nonetheless, the complexity involved with the transition metal catalysts, the toxicity often associated with the metals and the none-negligible amounts of waste produced during the reactions have caused significant drawbacks. The advent of green and sustainable chemistry brought organocatalysis into prominence (2021 Nobel Prize in Chemistry), allowing the field to emerge as an effective alternative to classical metal-based asymmetric catalysis. Small Molecule Organocatalysts (SMOs) have been used in a plethora of different synthetic transformations. Their stability to air excludes the need for inert conditions and ultra-dry solvents and thus minimizes overall research expenditure. Among all the SMOs reported throughout the years, N-heterocyclic carbenes (NHCs) have shown great promise, offering interesting prospects for both academic and industrial applications.
In the last decade, bio-hybrid DNA-based asymmetric catalysis (DAC) has appeared as an attractive tool providing excellent enantioselectivities on a broad range of reactions. DNAOrgCat aims at combining, for the first time, asymmetric organocatalysis and bio-hybrid catalysis to develop new, highly enantioselective, scalable and sustainable organocatalytic processes. To reach this goal, we will design, synthesize and ultimately evaluate a series of NHC-modified oligonucleotides on a model Stetter reaction. We will also develop sustainable catalytic systems based on recyclable, solid-supported, modified oligonucleotides, which will ultimately be implemented to large-scale continuous flow processes. By doing so, not only do we intend to expand the current frontiers of DNA-based asymmetric catalysis, we also wish to set a mind change and unquestionably place DNA-based catalysts in the chemists’ toolbox.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-PF-01

See all projects funded under this call

Coordinator

QUEEN MARY UNIVERSITY OF LONDON
Net EU contribution
€ 260 347,92
Address
327 MILE END ROAD
E1 4NS LONDON
United Kingdom
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data